ABT-199, a new Bcl-2-specific BH3 mimetic, is efficacious in vivo against mouse lymphomas without provoking thrombocytopenia.
Introduction
Whether cells live or die by apoptosis when confronted with diverse stresses, including radiation and chemotherapy, is determined by interactions between opposing factions of the Bcl-2 family of proteins 1 . Bcl-2 prevents apoptosis, as do The impact of ABT-737 and ABT-199 on tumor-bearing mice was rapid, with the WBC count dropping within 3 h ( Figure 1A ,B). By d6, the WBC count had dropped further in most mice, except for one bim -/-lymphoma (#324), which had a mixed phenotype (see Figure 1 legend;
supplemental Figure S1A ).
Platelet counts were low prior to treatment, presumably due to the tumor burden ABT-737 has been thought to act by displacing Bim from Bcl-2, thereby making it available to neutralise Mcl-1 or A1, which would otherwise contribute to resistance 1 3 . Surprisingly, however, the bim -/-tumors responded well to treatment. With ABT-199, survival was only modestly less than for those with bim +/+ tumors (P = 0.039) and with ABT-737, the response was comparable ( Figure 1E, F Figure S1B) .
Presumably a combination of other BH3-only proteins had sufficed to replace Bim. It will be important to determine if these findings extend to other Bcl-2-dependent tumor types, particularly in a clinical setting.
Long-term exposure to ABT-737 in vitro can result in the emergence of resistant clones through up-regulation of anti-apoptotic Bcl-2-related proteins 14 . To test whether selection was occurring during treatment in vivo, we compared 5 tumors from sick mice that had been treated earlier with a BH3 mimetic or vehicle (supplemental , it also results in an increase in Noxa (eg 16 ). CDK inhibitors down-regulate
Mcl-1 transcription 17 and purvalanol A has been shown to induce apoptosis of Mycoverexpressing cells and extend survival of mice transplanted with Eμ-myc tumors 18 .
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From For direct comparison with the earlier study, treatment was started on d4 rather than on d11. None of the lymphomas responded to bortezomib or purvalanol A as single agents. Tumor #9 responded better to ABT-737 plus bortezomib than ABT-737 alone (P = 0.02), the response being comparable (P=0.19) to that achieved with ABT-737 and low dose cyclophosphamide, but ABT-737/purvalanol was not significantly better than ABT-737 alone (P = 0.12). For tumor #12, there was no significant benefit with ABT-737 plus bortezomib versus ABT-737 alone (P=0.52), but the outcome with ABT-737/purvalanol was comparable to that achieved with ABT-737/cyclophosphamide (P=0.47). For tumor #16, ABT-737 produced complete remission as a single agent, all mice remaining healthy until the experiment was terminated at 150d (supplemental Table S2 ); the greater sensitivity may be due to higher levels of Puma and Noxa in this tumor (supplemental Figure S1B ). When treated with ABT-737 from d11 rather than d4, however, all mice transplanted with #16 had died by d50 ( Figure 1E ). This dramatic difference in outcome most likely reflects the relative tumour burden at the outset of treatment and longer treatment may have been more effective.
Early clinical trials for treating CLL with navitoclax 9 and now ABT-199 .
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For Figure S1A ), which would confer greater resistance. Tables S1, S2 ). With tumor #16, all mice treated with ABT-737 alone remained healthy until the experiment was terminated at d150 (supplemental Table S2 and data not shown; controls treated with vehicle were all dead by d35). 
